2nd Edition of Cell & Gene Therapy World Conference(CGTWC) 2026

Scientific Sessions

Overcoming Challenges in AAV Based Gene Therapy

Gene delivery by Adeno-Associated Virus (AAV) vectors is a popular technique. However, it has drawbacks, including immunological reactions. Optimizing its payload capacity, delivery efficiency, and insertional mutagenesis risk are obstacles that must be overcome. To overcome these problems, experts are creating new AAV serotypes with improved tissue specificity and efficiency, shortening production procedures to increase yield, and using genome-editing techniques to reduce insertional risks.

Related Sessions

CRISPR Cas9 and Beyond: Emerging Genome Editing Platforms
Precision Genome Editing: From Target Discovery to Clinical Application
Engineering the Immune System: Gene and Cell Based Modulation
Non Viral Gene Delivery Strategies: Safety, Scalability, and Translation
Stem Cell Derived Therapeutics: iPSCs, Organoids and Tissue Engineering
Allogeneic vs Autologous Cell Therapies: Manufacturing, Efficacy, and Access
Manufacturing for Personalized Medicine: Customised Cell Products at Scale
Analytics, Potency Assays, and Rapid Release Strategies
CGTs for Monogenic Disorders: Delivering the Cure
Gene and Cell Therapies in Oncology: CAR T, NK, TCR, Oncolytic Approaches
Neurological and Neurodegenerative Disease Applications of CGTs
Market Access, Health Economics, and Reimbursement in CGT
Global Access and Equity: Bridging the CGT Innovation Gap
The Future Landscape of Cell and Gene Therapies: 2030 and Beyond
Cell and Gene Therapy Clinical Development
Cell and Gene Therapy Pipeline Analysis